Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2

References

• World Health Organization. Weekly epidemiological update on COVID-19 Edition 83 - 15 March 2022. [accessed 2022 Mar 16]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—15-march-2022.
   Google Scholar
• Peng Y, Xu B, Sun B, Han G, Zhou YH. Importance of timely management of patients in reducing fatality rate of coronavirus disease 2019. J Infect Public Health. 2020;13(6):890–7. doi:10.1016/j.jiph.2020.04.015.
   PubMed Web of Science ®Google Scholar
• Hess PE, Wylie BJ, Golen T, Shainker SA, Zera C, Li Y. Keeping pregnant patients safe during COVID-19 pandemic. Matern Fetal Med. 2021;3(1):2–6. doi:10.1097/FM9.0000000000000072.
   PubMedGoogle Scholar
• Nieto-Calvache AJ, Padilla I, Tabares-Blanco MF, López-Girón MC, Vergara Galliadi LM. Fear is the path to the dark side: Unsafe delivery, one of the consequences of fear of the SARS-CoV-2 pandemic, a case report. Matern Fetal Med. 2021;3(4):292–94. doi:10.1097/FM9.0000000000000112.
   PubMedGoogle Scholar
• Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, Redondo-Pachón MD, Murphy B, Florman S, Cyrino LG, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20(11):3140–48. doi:10.1111/ajt.16185.
   PubMed Web of Science ®Google Scholar
• Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329–38. doi:10.1016/j.jinf.2021.01.022.
   PubMed Web of Science ®Google Scholar
• Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, Lee GM, Talbot HK, Romero JR, Oliver SE. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(49):1857–59. doi:10.15585/mmwr.mm6949e1.
   PubMed Web of Science ®Google Scholar
• Topol EJ. Messenger RNA vaccines against SARS-CoV-2. Cell. 2021;184(6):1401. doi:10.1016/j.cell.2020.12.039.
   PubMed Web of Science ®Google Scholar
• Dal-Ré R, Caplan AL, Gluud C, Porcher R. Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. Ann Intern Med. 2021;174(2):258–60. doi:10.7326/M20-7357.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. Nature. 2021;594(7862):161–62. doi:10.1038/d41586-021-01497-8.
   PubMed Web of Science ®Google Scholar
• Mehraeen E, Dadras O, Afsahi AM, Karimi A, MohsseniPour M, Mirzapour P, Barzegary A, Behnezhad F, Habibi P, Salehi MA, et al. Vaccines for COVID-19: a review of feasibility and effectiveness. Infect Disord Drug Targets. 2021. doi:10.2174/1871526521666210923144837.
   PubMedGoogle Scholar
• Gharpure R, Patel A, Link-Gelles R. First-Dose COVID-19 vaccination coverage among skilled nursing facility residents and staff. Jama. 2021;325(16):1670–71. doi:10.1001/jama.2021.2352.
   PubMed Web of Science ®Google Scholar
• Quiroga B, Sánchez-Álvarez E, Goicoechea M, de Sequera P. Spanish Society of Nephrology Council. COVID-19 vaccination among Spanish nephrologists: acceptance and side effects. J Healthc Qual Res. 2021;36(6):363–69. doi:10.1016/j.jhqr.2021.05.002.
   PubMedGoogle Scholar
• Whiteman A, Wang A, McCain K, Gunnels B, Toblin R, Lee JT, Bridges C, Reynolds L, Murthy BP, Qualters J, et al. Demographic and social factors associated with COVID-19 vaccination initiation among adults aged ≥65 years - United States, December 14, 2020-April 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(19):725–30. doi:10.15585/mmwr.mm7019e4.
   PubMed Web of Science ®Google Scholar
• Xu B, Gao X, Zhang X, Hu Y, Yang H, Zhou YH. Real-World acceptance of COVID-19 vaccines among healthcare workers in perinatal medicine in China. Vaccines (Basel). 2021;9(7):704. doi:10.3390/vaccines9070704.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Shen P, Xu B, Chen Y, Luo Y, Dai Y, Hu Y, Zhou YH. COVID-19 vaccination coverage among healthcare workers in obstetrics and gynecology during the first three months of vaccination campaign: a cross-sectional study in Jiangsu province, China. Hum Vaccin Immunother. 2021;17(12):4946–53. doi:10.1080/21645515.2021.1997297.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. Jama. 2021;326(1):35–45. doi:10.1001/jama.2021.8565.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes AL, Lutrick K, et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–29. doi:10.1056/NEJMoa2107058.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdox1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Pan HX, Liu JK, Huang BY, Li GF, Chang XY, Liu YF, Wang WL, Chu K, Hu JL, Li JX, et al. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021;134(11):1289–98. doi:10.1097/CM9.0000000000001573.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doganay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Blais JE, Wei Y, Chui CSL, Chan EW, Wong ICK. Inconsistent safety outcome reporting in randomized clinical trials of COVID-19 vaccines complicates informed medical decisions. Drug Saf. 2021;44(11):1121–23. doi:10.1007/s40264-021-01108-5.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhu L, Zhu Y, Ye Q, Yu X, Fu M, Lu J, Li X, Huang Y, Zhang J, et al. Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China. Hum Vaccin Immunother. 2021;17(9):2863–67. doi:10.1080/21645515.2021.1913964.
   PubMed Web of Science ®Google Scholar
• Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, Chen HX. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20(7):891–98. doi:10.1080/14760584.2021.1925112.
   PubMed Web of Science ®Google Scholar
• Zhu JS, Zhang MX, Chien CW, Yang WY, Shi GF, Qiu S, Tung TH, Chen HX. Sex differences in adverse reactions to an inactivated SARS-CoV-2 vaccine among medical staff in China. Front Med (Lausanne). 2021;8:731593. doi:10.3389/fmed.2021.731593.
   PubMed Web of Science ®Google Scholar
• Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219–26. doi:10.1016/j.ijid.2021.08.013.
   PubMed Web of Science ®Google Scholar
• Ali Sahraian M, Ghadiri F, Azimi A, Naser Moghadasi A. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine. 2021;39(43):6347–50. doi:10.1016/j.vaccine.2021.09.030.
   PubMed Web of Science ®Google Scholar
• Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, Abbas H, Rababah L, Rabadi M, Karasneh R, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother. 2022;18(1):1981086. doi:10.1080/21645515.2021.1981086.
   PubMed Web of Science ®Google Scholar
• Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021;39(25):3313–14. doi:10.1016/j.vaccine.2021.04.066.
   PubMed Web of Science ®Google Scholar
• Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239–49. doi:10.1007/s00281-018-0726-5.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577–99. doi:10.1146/annurev-cellbio-100616-060718.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdox1 nCov-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Riad A, Pokorná A, Mekhemar M, Conrad J, Klugarová J, Koščík M, Klugar M, Attia S. Safety of ChAdox1 nCov-19 vaccine: Independent evidence from two EU States. Vaccines (Basel). 2021 ;9(6):673. doi:10.3390/vaccines9060673.
   PubMed Web of Science ®Google Scholar
• Alghamdi AN, Alotaibi MI, Alqahtani AS, Al Aboud D, Abdel-Moneim AS. Bnt162b2 and ChAdox1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees. Front Med (Lausanne). 2021;8:760047. doi:10.3389/fmed.2021.760047.
   PubMed Web of Science ®Google Scholar
• Mehraeen E, SeyedAlinaghi S, Karimi A. Can children of the Sputnik V vaccine recipients become symptomatic? Hum Vaccin Immunother. 2021;17(10):3500–01. doi:10.1080/21645515.2021.1933689.
   PubMed Web of Science ®Google Scholar
• Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, Zou H, Sun C. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021;10(1):94. doi:10.1186/s40249-021-00878-5.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Zee JST, Lai KTW, Mks H, Leung ACP, Chan QWL, Esk M, Lee KH, Lau CC, Yung RWH. Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: Preliminary results. Hong Kong Med J. 2021;27(4):312–13. doi:10.12809/hkmj219605.
   PubMed Web of Science ®Google Scholar
• Male V. Menstrual changes after COVID-19 vaccination. Bmj. 2021;374:n2211. doi:10.1136/bmj.n2211.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–84. doi:10.1016/S0140-6736(21)02000-6.
   PubMed Web of Science ®Google Scholar